Tiffany obtained a Master's degree in Integrative Biology and Physiology at Sorbonne University (Physiology and Human Pathophysiology course), and a Master's degree in Therapy and Technology for Living Analysis at Sorbonne Paris Nord University. During her M2 internships, she studied the molecular basis of a new subtype of CDG syndrome at the Centre de Recherche sur l'Inflammation (CRI) in Paris, and investigated new anti-cancer pharmaceutical approaches at the CHU Sainte-Justine Research Centre in Montreal. In May 2023, she joined the Oncopharmacology & Cutaneous Pharmacotoxicology department of IBMM, hosted by the University of Montpellier, as a research engineer, working on the mechanism of action of new active molecules on malignant melanoma.